Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Elizabeth Smyth MD

Elizabeth Smyth MD

Consultant Medical Oncologist, Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

Dr. Elizabeth (Lizzy) Smyth works as a consultant medical oncologist in upper gastrointestinal oncology at Oxford University Hospitals NHS Foundation Trust with a research focus in oesophagogastric cancer. Her interests are clinical trials and translational research, and she has worked on trial design and management of national and international investigator-initiated trials. She is committed to furthering national and international collaboration in gastrointestinal cancer research and improving outcomes for patients with oesophagogastric cancer, and to that end is very involved with EORTC efforts in gastrointestinal tract cancer. In 2022, Dr. Smyth was a founding member of the United Kingdom and Ireland Oesophagogastric Cancer Group (UKIOG), and she is a trustee of the UKIOG Charity.

Dr. Smyth has published more than 170 peer-reviewed manuscripts in her field, including in high-impact journals. She is highly active in ESMO and is the senior author of the recent ESMO Clinical Cancer Guidelines for both gastric and oesophageal cancer.

Recent Contributions to PracticeUpdate:

  1. Trastuzumab Deruxtecan for Patients With HER2-Positive Advanced Gastric or GE Junction Adenocarcinoma
  2. Pembrolizumab vs Paclitaxel in Second-Line Treatment of Advanced Gastric Cancer
  3. Margetuximab Plus Checkpoint Inhibition for HER2+ Advanced GE Junction or Gastric Cancer
  4. Overcoming Heterogeneity to Develop Targeted Therapies for Gastroesophageal Cancer
  5. ASCO: Perioperative Targeting of HER2 for Gastroesophageal Cancer
  6. ASCO: Current Data and Outlook for Targeting HER2 in Gastrointestinal Cancer
  7. ASCO: Promising Results for Trastuzumab Deruxtecan for HER2+ Gastric Cancer
  8. ASCO: New Data and Implications for Immunotherapy in Gastric Cancer
  9. Nivolumab vs Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma
  10. Margetuximab Plus Pembrolizumab for Patients With HER2+ GE Junction Adenocarcinoma

Elsewhere

Recently Updated